Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE

Phase I Clinical Trial of CD19-targeting Chimeric Antigen Receptor T Lymphocyte (MC-1-50) for the Treatment of Refractory Adult Systemic Lupus Erythematosus(SLE)

This is a single-arm, open, dose-increasing and dose-expanding phase I clinical trial to investigate the safety, tolerability and cytodynamic characteristics of MC-1-50 cell preparation, and to preliminatively observe the efficacy of MC-1-50 cell preparation in patients with refractory SLE, and to explore the applicable dose regimen for phase II clinical trials.

Study Overview

• Status: Recruiting
• Conditions: Systemic Lupus Erythematosus (SLE); Refractory
• Intervention / Treatment: Biological: MC-1-50

Detailed Description

Based on the specific CD19-targeting CAR-T developed by PrimeCARTM platform, the cell preparation time is about 3 days, which can greatly shorten the waiting time of patients, improve production efficiency and reduce production costs.At the same time, MC-1-50 products contain a high proportion of T naive cells, which can play a therapeutic role at a very low infusion dose and improve safety.

In this study, three dose groups were composed of 0.3×10^5/kg, 1×10^5/kg and 3×10^5/kg CAR-positive cells, respectively.All subjects received only one infusion of MC-1-50 cells.

• Study Type: Interventional
• Enrollment (Estimated): 12
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Jing Xue, M.D.; Phone Number: +8613858121751; Email: xuej@zju.edu.cn
• Study Contact Backup: Name: Zhu Chen, M.D.; Phone Number: +8613956963042; Email: doczchen@gmail.com

Study Locations

• China
  • Anhui
    • Hefei, Anhui, China
      • Recruiting
      • The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
      • Contact: Zhu Chen, M.D.; Phone Number: +8613956963042; Email: doczchen@gmail.com
  • Zhejiang
    • Hangzhou, Zhejiang, China
      • Recruiting
      • The Second Affiliated Hospital of Zhejiang University School of Medicine
      • Contact: Jing Xue, M.D.; Phone Number: +8613858121751; Email: xuej@zju.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. The patient or their guardian agrees to participate in this clinical trial and sign the ICF, indicating their understanding of the purpose and procedures of this clinical trial and willingness to participate in the study;
2. Age ≥ 18 years old , gender not limited;
3. Patients diagnosed with SLE according to the 2019 EULAR/ACR classification criteria,And by hydroxychloroquine, sufficient glucocorticoid (≥1mg/kg/d prednisone or equivalent amount of other hormones), to less than 2Treatment with immunosuppressants (including cyclophosphamide, motecophanate, azathioprine, methotrexate, cyclosporine, tacrolimus, sirolimus, leflunomide, etc.), and at least one approved biological agent (including titacept, Beliuzumab, etc.), with a total duration of treatment ≥3 months, still in a disease active state, or unable to tolerate conventional therapy;
4. SLEDAI-2K score ≥7 points;
5. Autoantibody test results are positive: ANA antibody positive and/or serum anti-DSDNA positive;

6. Adequate renal, hepatic, pulmonary and cardiac function defined as:

   1. Cardiac function: Echocardiography indicates left ventricular ejection fraction ≥ 50%;
   2. Renal function: serum creatinine ≤ 2.0 × ULN, or creatinine clearance rate ≥ 60ml/min (Cockcroft Gault formula);
   3. Hepatic function: ALT and AST ≤ 3.0 × ULN (may be relaxed to ≤ 3.0 × ULN in cases of combined liver infiltration);
   4. Total bilirubin ≤ 2.0 × ULN (Gilbert syndrome requires total bilirubin ≤ 3.0 × ULN);
   5. Pulmonary function: Blood oxygen saturation is ≥ 92% in non oxygen state.
7. No serious mental disorders;
8. Meet standards for apheresis or venous blood collection, and no other cell collection contraindications;
9. Women of childbearing age who have a negative blood pregnancy test and all subjects agree to use reliable and effective contraceptive methods (excluding safe period contraception) for contraception within one year after receiving MC-1-50 cell infusion from the time of signing the informed consent form. Including but not limited to: abstinence, implantable progestogen contraceptives that can inhibit ovulation; Intrauterine device (IUD); Intrauterine hormone release system; Spouse vasectomy; Compound hormone contraceptives that can inhibit ovulation (oral, vaginal, and transdermal); Progesterone contraceptives (oral or injectable) that can inhibit ovulation; When male subjects have sex with fertile women, they must agree to use barrier contraception (such as condom plus spermicidal foam/gel/film/emulsion/suppository). At the same time, participants should commit not to donate eggs (oocytes, oocytes) or sperm for assisted reproduction within one year after cell infusion.

Exclusion Criteria:

1. There were severe active central nervous system lupus that required therapeutic intervention at the time of screening;
2. Acute severe nephritis: had or was undergoing renal replacement therapy within 3 months prior to reinfusion, or had significant renal deterioration that the investigator believed was likely to cause the subject to require high doses of corticosteroids (prednisone ≥1mg/kg/ day or equivalent of other hormones), cyclophosphamide, or mycophanate during the first 3 months of the study;Clinical stable lupus nephritis that can be controlled during screening can be considered;
3. There were other lupus crises that were not controlled at the time of screening;
4. Individuals who have received CAR-T therapy or other gene modified cell therapies;
5. Combined with other autoimmune diseases requiring systemic treatment;
6. HBsAg or HBcAb positive and HBV DNA test greater than the normal range;HCV antibody positive and HCV RNA detection greater than the normal range;HIV antibody positive;Treponema pallidum antibody positive;

7. Suffered from any of the following heart diseases:

   1. New York Heart Association (NYHA) stage III or IV congestive heart failure;
   2. Within the 6 months prior to enrollment, there has been a myocardial infarction, or a coronary artery bypass grafting (CABG) or stent implantation surgery has been performed;
   3. History of ventricular arrhythmias requiring treatment or unexplained syncope (excluding cases caused by vasovagal or dehydration);
   4. History of severe non-ischemic cardiomyopathy;
8. Uncontrollable infection in the 1 weeks before enrollment;
9. History of solid organ transplantation or hematopoietic stem cell transplantation prior to screening；
10. Cerebrovascular accident or seizure occurred within 6 months prior to screening；
11. Deep vein or deep artery embolism event within the past 6 months prior to screening;
12. history of malignant neoplasms (other than tumors with no active lesion and ending treatment > 2 years ago, and adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery);
13. (attenuated) Live vaccine ≤ 4 weeks prior to screening;
14. Have participated in other clinical trials within one month or five drug half lives (whichever is shorter) before enrollment;
15. Women who are pregnant or breastfeeding, and male or female subjects who plan to have children within 1 year after receiving MC-1-50 cell infusion;
16. Other situations considered by the investigator to be unsuitable to participate in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MC-1-50; Patients will be be treated with CD19 CAR- T cells	Biological: MC-1-50; A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion chemotherapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	The incidence of adverse events after CAR-T cell infusion was assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, version 5.0)	1 month
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Dose-limiting toxicity after CD19 CAR-T cell infusion	1 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
TMAX of MC-1-50 cell preparation[Cell dynamics]	TMAX is defined as the time to reach the highest concentration	3 months
Pharmacodynamics of MC-1-50 cell preparation[Cell dynamics]	The clearance degree of CD19-positive B cells in peripheral blood was detected by flow cytometry at the visit points specified in the research protocol	3 months
CMAX of MC-1-50 cell preparation [Cell dynamics]	CMAX is defined as the highest concentration of MC-1-50 cells expanded in peripheral blood	3 months
Immunogenicity of pCAR-19B cells	The anti-CAR antibody was detected by ELISAt the visit points specified in the research protocol	3 months
Validity endpoint of MC-1-50 cells [Efficacy]	3M SRI-4 response rate, 6M LLDAS, DORIS response rate，SLEDAI-2K score, PGA, and BILAG-2004 change from baseline	3 months
AUCS of MC-1-50 cells [Cell dynamics]	AUCS is defined as the area under the curve in 28/90 days	3 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Response rate after MC-1-50 infusion [Long-term Efficacy]	The DORIS response rate, LLDAS maintenance rate, and SRI-4 response rate at the remaining sites after reinfusion when other drugs (including hormones, hydroxychloroquine, immunosuppressants, and biologics) were discontinued.And changes from baseline in SLEDAI-2K scores, PGA scores, BILAG-2004 scores, and serological indicators, including anti-DSDNA, anti-nuclear antibodies, and complement C3 and C4 levels	2 years
The rebuilding of the immune system	Proportion of B-cell subtypes at each site and their association with reduced disease activity	2 years

Collaborators and Investigators

• Sponsor: Chongqing Precision Biotech Co., Ltd
• Collaborators: Second Affiliated Hospital, School of Medicine, Zhejiang University

Study record dates

Study Major Dates

• Study Start (Actual): June 12, 2025
• Primary Completion (Estimated): May 4, 2026
• Study Completion (Estimated): February 16, 2028

Study Registration Dates

• First Submitted: March 18, 2025
• First Submitted That Met QC Criteria: March 18, 2025
• First Posted (Actual): March 24, 2025

Study Record Updates

• Last Update Posted (Actual): December 22, 2025
• Last Update Submitted That Met QC Criteria: December 18, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: Systemic Lupus Erythematosus; CAR T-Cell therapy
• Additional Relevant MeSH Terms: Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Skin and Connective Tissue Diseases; Lupus Erythematosus, Systemic
• Other Study ID Numbers: PB13

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No